Crescent Biopharma (CBIO) Total Liabilities (2013 - 2026)
Crescent Biopharma (CBIO) posted quarterly Total Liabilities of $19.5 million for Q2 2026, up 7.28% year-over-year from $18.2 million in Q2 2025, and up 27.61% quarter-over-quarter from $15.3 million in Q1 2026.
Crescent Biopharma (CBIO) Total Liabilities (2013 - 2026) Analysis & Trends
Crescent Biopharma (CBIO) has reported Total Liabilities for 14 consecutive years, with $19.5 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Total Liabilities rose 7.28% year-over-year to $19.5 million; the TTM figure through Jun 2026 stood at $19.5 million (up 7.28% YoY), while the FY2025 annual figure was $37.3 million, down 20.84% from the prior year.
- Total Liabilities climbed to $19.5 million in Q2 2026 per CBIO's latest filing, from $15.3 million in the prior quarter.
- Across five years, Total Liabilities topped out at $47.1 million in Q4 2024 and bottomed at $2.6 million in Q1 2025.
- Historically, Total Liabilities has averaged $13.5 million across 5 years, with a median of $8.4 million in 2022.
- Annual changes were most pronounced in 2024 — Total Liabilities soared 582.35% — and 2025, when it tumbled 50.57%.
- Crescent Biopharma's Total Liabilities stood at $8.9 million in 2022, then decreased by 22.28% to $6.9 million in 2023, then jumped by 582.35% to $47.1 million in 2024, then retreated by 20.84% to $37.3 million in 2025, then plunged by 47.69% to $19.5 million in 2026.
- Business Quant data shows CBIO's Total Liabilities at $19.5 million in Q2 2026, $15.3 million in Q1 2026, and $37.3 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | Crescent Biopharma | 1.05 Bn | 875.92 Mn | - | 19.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 19.50 Mn |
| Mar 31, 2026 | 15.28 Mn |
| Dec 31, 2025 | 37.28 Mn |
| Sep 30, 2025 | 21.63 Mn |
| Jun 30, 2025 | 18.18 Mn |
| Mar 31, 2025 | 2.62 Mn |
| Dec 31, 2024 | 47.10 Mn |
| Sep 30, 2024 | 4.32 Mn |
| Jun 30, 2024 | 4.36 Mn |
| Mar 31, 2024 | 5.29 Mn |
| Dec 31, 2023 | 6.90 Mn |
| Sep 30, 2023 | 6.65 Mn |
| Jun 30, 2023 | 7.02 Mn |
| Mar 31, 2023 | 6.74 Mn |
| Dec 31, 2022 | 8.88 Mn |
| Sep 30, 2022 | 7.84 Mn |
| Jun 30, 2022 | 9.32 Mn |
| Mar 31, 2022 | 13.43 Mn |
| Dec 31, 2021 | 12.74 Mn |
| Sep 30, 2021 | 11.38 Mn |